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Abstract 
Background: According to epidemiological studies, leukemia is among the five most 
common cancers in Iran. Keeping efforts to estimate survival is critical to monitoring and 
improving patients’ quality of life with leukemia. The purpose of this study was to 
evaluate the 5-year survival rate of leukemia patients in Iran using meta-analysis method.  
Methods: This meta-analysis was carried out according to studies that adhere to inclusion 
and exclusion criteria during enrolment. The valid Iranian databases included: Medex, 
Magiran, SID, and Medlib, along with international data bases, namely, Scopus, Pubmed, 
and ISI were searched to find relevant articles. After determining the heterogeneity 
between studies, the random effects models were used to estimate pooled survival in 
leukemia patients.  
Results: In total, 18 studies involving 2517 participants were included in this meta-
analysis. The pooled 5-year survival rate was 0.56 % (95% CI, 0.54 to 0.58). According to 
types AML and ALL, the 5-year survival rates in Iran were 35.0 % (95% CI: 32.0-38.0) 
and 57.0 % (95% CI: 54.0-60.0), respectively. 
Conclusion: Based on our findings, slightly less than 50% of leukemia deaths happened in 
the first 5 years after diagnosis, which is lower than the global average. 
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Acording to National Cancer Registry reports; stomach, esophagus, colon-rectum, 
bladder and leukemia cancers are the five most common types of cancer in Iranian males 
(1). Distribution of cancers in the different provinces of Iran does not have the same 
pattern, i.e in Fars province, leukemia ranks the first and second cancer in males and 
females, respectively (2). Generally, this malignancy is more common among the 
developed countries (3). The results of age-adjusted death rate, based on 2009-2013 USA 
statistics of deaths, showed that the incidence rate of leukemia was 13.5 per 100,000 in 
men, and also 6.9 per 100,000 in both genders (4). In recent decades, the 5-year survival 
rate of leukemia patients has increased due to the improvement of medical procedures and 
treatments. So the 5-year survival rate in individuals with age less than 20 years has 
reached to 89% (5, 6). Supportive cares in the USA have improved  the 5-year survival 
rate in  patients with leukemia up to 70% in recent years (7). In Iran, a 5-year survival rate 
is lower than the developed countries, hence, according to reports, the index rates for ALL 
and AML patients were 53.3% and 25.0%, respectively (8, 9). The important reason for 
this increasing rate of survival in leukemia patients wase associated to rigorous treatment 
accompanied stem cell transplantation (10). 
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The important factors that are acknowledged can be 
predicting survival in leukemia patients including;  some 
patients’ resistance to treatment in laboratory factors 
(number of white and red blood cells, the means of 
corpuscular hemoglobin, sodium, potassium and calcium); 
smoking, patients’ age, bone marrow transplants and history 
of disease (11). However, the exact effect of some of these 
factors on survival is unclear; sex and gender (12), may be 
due to different methods in different studies. 
Keeping the researcher's effort to estimate survival is 
very useful in monitoring and improving the quality of life of 
patients with leukemia, which can lead to conducting better 
screening programs and discovering new treatments. In this 
meta-analysis, we evaluated recent relevant studies towards 
the 5-year survival rate of leukemia in Iran. 
 
 
Methods  
Data sources: This meta-analysis was carried out to estimate 
the survival rates of leukemia in Iran according to studies 
that adhered to inclusion and exclusion during enrolment 
according to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines (13). The 
inner covering; Iran Medex, Magiran, SID, and Medlib, also 
international data bases including; Scopus, Pubmed, and ISI 
were searched to find the relevant articles. 
Search strategy: Title searching for studies was done by 
MeSH heading leukemia and other keywords including; Iran, 
survival rate, and rate. The search strategies in pubmed were 
("survival rate"[MeSH Terms] OR ("survival"[All Fields] 
AND "rate"[All Fields]) OR "survival rate"[All Fields]) 
AND ("leukaemia"[All Fields] OR "leukemia"[MeSH 
Terms] OR "leukemia"[All Fields]) AND ("Iran"[MeSH 
Terms] OR "Iran"[All Fields]). All titles and next abstracts 
were checked to find out the most relevant articles. Next, the 
full texts of related articles were assessed including relevant 
articles in meta-analysis. In the final step, cross-referring 
was done to increase search sensitivity. 
Inclusion and exclusion criteria: At the first step to 
enhance sensitivity of search, all epidemiologic studies 
regarding survival for leukemia patients in Iran in Persian 
and English language were enrolled. The time period of this 
study was 2008-2016. After primary search, we reviewed the 
full text and the inclusion criteria were; at least a 5-year 
follow-up of patients, estimation of 5-year survival rate. In 
this study, studies with less than 5-years of follow-up period, 
and also articles of poor quality (based on NOS scale) were 
excluded. 
Data extraction: Screening and review of studies was done 
by two authors independently. The key information about the 
first author’s name, year of publication, study design, 
patients characteristics, period of data acquisition, and 5-year 
survival were extracted in a standardized form. Afterwards, 
the details were imported to the software to apply meta-
analysis. 
Quality assessment: The methodological methods included 
studies assessed by Newcastle-Ottawa Scale(14). Eventually 
the articles were classified to three groups of studies, high 
(>7 points), medium (6-7 points), and low quality (<6 points).  
Statistical analysis: The heterogeneity between studies was 
calculated by I² statistics. Since the heterogeneity in pooled 
estimate and in subgroups was higher than 25 percent, 
therefore the random effects model was applied to estimates 
of the overall 5-year survival rate (15). The Begg’s test was 
used to assessing publication bias in this study (16). Analysis 
was done by Stata software Version 11.2 at the significance 
level of 5%. 
 
 
Results 
In the initial search, 290 titles in all databases were 
recognized, they were screened to enrol more relevant 
studies and 103 abstracts were recognized and added as 
relevant studies according to meta-analysis. Abstracts were 
reviewed to find the best studies that met our inclusion 
criteria. Full texts of 37 articles were reviewed to identify 
final meta-analysis studies. We excluded 19 articles because 
of their irrelevance according to exclusion criteria. After 
excluding the studies that did not fulfill the inclusion criteria, 
finally 18 relevant studies were determined for meta-analysis 
(figure 1). Important characteristics of included studies were 
shown in table 1. The study duration was from 2008 to June 
2016. Of total 2517 survivors, 836 were ALL, 1070 were 
AML, 190 were CLL and about 502 were CML. Of the 18 
included studies, seventeen articles had a cross-sectional 
design and one of them was retrospective design. Stage of 
flow up in three studies was different, one study was 
hematopoietic stem cell transplant (HSCT) (17), another one 
was after chemotropic treatment program (18) and the third 
study was after treatment with imatinib mesylate (19). In 
other 15 studies, the patients were identified during the 
hospital-initiated treatment. Data in all studies were based on 
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hospital and medical record. Age range in 8 articles was 
below 15 years old while more than 15 years old in 10 
studies. The overall 5- year survival rate in leukemia patients 
in Iran was 0.56% (0.54 to 0.58, 18 studies). The 
heterogeneity between studies was significant (X
2
 = 64.37, 
p<0.001, I 
2
 = 97.7%, 95% CI 96.4–98.3) (figure 2).   
5-year survival rates based on type of leukemia are 
shown in figure 3. Based on the AML and CML the 5-year 
survival rate in Iran were 35.0 % (95% CI: 32.0-38.0, 9 
studies) and 83.0 % (95% CI: 79.0-86.0, 2 studies), 
respectively. 5-year survival rates for other types included 
ALL and CLL were 57.0 % (95% CI: 54.0-60.0, 6 studies) 
and 64.0 % (95% CI: 55.0-73.0, 1 studies) respectively. 
Possibility of sources for heterogeneity was assessed by 
subgroup analysis. When we obtained the heterogeneity with 
regard to quality of papers, the positive heterogeneity did not 
show yet (p<0.001). According to table 2, a 5- year survival 
rate paper with high quality is lower than the articles with 
low quality and also higher than medium quality papers. In 
patients aged below or more than 15 years old, 5- survival 
rate were 61.0 % (95% CI: 58.0-64.0, 8 studies) and 53.0 % 
(95% CI: 51.0-55.0, 10 studies), respectively. 
Results of meta-regression are shown in figure 4 
according to the year of publication and the number of 
subjects did not have association with heterogeneity in 
outcome. Thus, the year of publication and number of 
subjects were not related to causes of variability in the five 
year survival rate results (reg coef = 0.347, p=0.65) and (Reg 
Coef = 0.358, p=0.128), respectively (figure 4).  
Publication bias was assessed by funnel plots, according 
to them we did not find evidence for publication bias (bias: 
3.21, 95% CI= -09.14–18.12; p=0.668), consequently, our 
research study was considered the most published article in 
this subject (figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. follow chart of included studies 
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Table 1. Characteristics of studies included in meta analysis 
 
Ref. Author name, 
Year of Pub 
Leukemia  type (N) Years of flow 
sitting 
Age 5-year 
survival 
rate 
Quality of 
final articles 
Stage of evaluation 
ALL AML CLL CML 
(20) Payandeh, M. 
2015 
  109  2006-2014 
Kermanshah 
15  64 Medium After treatment in 
hospitalized patients 
(8) Hashiani, A. 
2013 
179 64   2004-2008 
Shiraz 
15  53.3 High After treatment in 
hospitalized patients 
(21) Allahyari, A. 
2016, 
 
 
96   2009-2015 
Mashhad 
15  26.6 Medium After treatment in 
hospitalized patients 
(22) Karimi, M. 
2012 
76    1995-2000 
Shiraz 
15  72.5 High After treatment in 
hospitalized patients 
(23) Payandeh, M. 
2015, 
 
 
  85 2002-2014 
Kermanshah 
15  79.7 Medium After treatment in 
hospitalized patients 
(24) Akramipour,R, 
2007 
 
 
40   1996-2000 
Ahvaz 
15  35 Low After treatment in 
hospitalized patients 
(25) Sanaat, Z. 
2010 
 
 
207   2001-2009 
Tabriz 
15  24.6 Low After treatment in 
hospitalized patients 
(26) Saffar, A. 
2015 
 
 
85   2008-2013 
Tehran 
15  22 Medium After treatment in 
hospitalized patients 
(27) Hashemi AS, 
2009 
 
 
56   2001-2007 
Yazd 
15  88.5 Low After treatment in 
hospitalized patients 
(17) Sayehmiri, K. 
2008 
206    1993-2007 
Tehran 
15  52 High after hematopoietic stem 
cell transplant (HSCT) 
(18) Ashrafi, F. 
2013 
 
 
94   2002-2010 
Isfahan 
15  18 High After  chemotropic 
treatment 
(28) Teshnizi,S. 
2013 
102 95   2006-2009 
Isfahan 
15  50.3 Low After treatment in 
hospitalized patients 
(29) Mashhadi, M.A. 
2012 
 
 
66   2003-2010 
Zahedan 
15  44.8 High After treatment in 
hospitalized patients 
(9) Sanaat, Z. 
2011 
 
 
142   2001-2009 
Tabriz 
15  25 Low After treatment in 
hospitalized patients 
(30) Mousavinasab, 
N. 2015 
84 13   2006-2014 15  79.7 Low After treatment in 
hospitalized patients 
(31) Ansari,Sh, 
2007 
 
 
83   1988-2003 
Tehran 
15  58 Medium After treatment in 
hospitalized patients 
(19) Jalaeikhoo, H. 
2011 
 
 
  417 2004-2010 
Tehran 
15  83 High After treatment with 
imatinib mesylate 
(32) Parvareh,M. 
2015, 
189 
 
29   1998-2009 
Kerman 
15  51 High After treatment in 
hospitalized patients 
 
 
 Caspian J Intern Med 2018; 9(4):316-324  
320                                                                               Veisani Y, et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 5-year survival rates of leukemia patients in Iran 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 5-year survival rates of leukemia patients in Iran according to type 
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Figure 4. Results of meta-regression by plots, the covariates are subjects and year of publication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Funnel plot according to Begg's approach showing the mean differences in the 5-year survival rates according to 
enrolled articles. 
 
Discussion 
The present meta-analysis demonstrated the 5-year 
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China 81.8% (34), India 51% (35) and 69.9% in Korea (3).  
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meta-regression findings; publication year, quality of 
articles, and number of patients in each study were not  
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survival rate. One report, based on large groups of AML 
patients in the USA, showed that 65% of those aged less than 
15 years survive from leukemia after 5 years, and this 
proportion for patients in 15-25 year’s age group, 25-65 
years age group, and up to 65 years were 60%, 40% and 5%, 
respectively. ALL has better outlook and five survival rates 
were 70% after diagnosis overall. This proportion for 15 
years, or younger than 15 years old was 90%, 15-25 years 
age group was 70%, 26-64 years age group was 40%, and in 
patients aged 65 or older was 15% after diagnosis (4). 
As shown previously, survival in younger individuals is 
better than older patients (36), genetic abnormalities  
diminish survival in leukemia patients, late diagnosis have a 
bad outlook for survival in all types of cancers (37, 38), plus 
high count of white blood cells is a predictor for better 
survival (39). The important limitations in current study are 
at first, some age groups (5<) were excluded due to the 
limitation in years of follow-up. Second, we evaluatd long 
term survival and survival less than 5 year was not estimated 
in the present meta-analysis. Third, some of the important 
predictors for heterogeneity such as data sources, length of 
follow-up and stage of cancer diagnosis were not assessed 
due to the lack of enrolled studies. Fourth, data sources in 
most primary studies were based on hospital records, as a 
result, they have some difficulties in their generalizability 
because data were not gathered for the purpose of 
investigation. Finally, typing mistakes and missing data are 
the other limitations in these sources. 
We can conclude that we enrolled 18 studies so that we 
could get reliable results about the 5-year survival rates of 
leukemia in Iran. We found that a 5-year survival rate in 
AML patients is lower than ALL patients, as well as 15 and 
below of age have shown a better prognosis compared with 
adults. According to these results, future research should be 
conducted to increase survival in leukemia patients; 
furthermore, guidance for clinicians can help improve long-
term survival in patients with leukemia. 
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